A real-world analysis reveals that tildrakizumab is highly effective and safe in patients with moderate-to-severe plaque ...

The coprimary endpoints were the proportion of zasocitinib-treated patients achieving static Physician Global Assessment (sPGA) of clear (0) or almost clear (1) and Psoriasis Area and Severity Index ...

Takeda Pharmaceutical Co. announced that its oral psoriasis drug zasocitinib proved safe and effective in late-stage trials, ...

Today, Takeda announced positive topline results from 2 pivotal phase 3 trials of zasocitinib (TAK-279; Takeda), demonstrating superiority over placebo across key efficacy end points in adults with ...

Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, announced new Phase 3b topline Week 16 results from Cohort A of the VISIBLE trial, the first prospective, large-scale, randomized-controlled ...

Please provide your email address to receive an email when new articles are posted on . Bimzelx (bimekizumab-bkzx) is the first and only interleukin 17A and 17F inhibitor approved in this indication.

Bimzelx is available as a single-dose prefilled autoinjector or prefilled syringe containing 160mg/mL of solution. Bimzelx ® (bimekizumab-bkzx) is now available for the treatment of moderate to severe ...

Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. 100% of patients treated with 150 mg, 300 mg and 600 mg ...

Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

Oral roflumilast showed potential as a nonbiologic systemic therapy for moderate to severe psoriasis, offering an alternative ...